[go: up one dir, main page]

AR122409A1 - Tratamiento de la fenilcetonuria con aav y formulaciones terapéuticas - Google Patents

Tratamiento de la fenilcetonuria con aav y formulaciones terapéuticas

Info

Publication number
AR122409A1
AR122409A1 ARP210100824A ARP210100824A AR122409A1 AR 122409 A1 AR122409 A1 AR 122409A1 AR P210100824 A ARP210100824 A AR P210100824A AR P210100824 A ARP210100824 A AR P210100824A AR 122409 A1 AR122409 A1 AR 122409A1
Authority
AR
Argentina
Prior art keywords
concentration
pharmaceutical composition
agent
aav
phenylketonuria
Prior art date
Application number
ARP210100824A
Other languages
English (en)
Inventor
Peter Colosi
Hassibullah Akeefe
Geoffrey Berguig
Rajeev Mahimkar
Haoling Weng
Zhonghua Gu
Marcus Wong
Kidisti Araya
Joyce Chou
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of AR122409A1 publication Critical patent/AR122409A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicación 1: Una composición farmacéutica que comprende partículas de rAAV a una concentración de al menos 1E13 vg/ml a aproximadamente 1E14 vg/ml que comprende fosfato de sodio a una concentración de aproximadamente 5 a aproximadamente 15 mM, cloruro de sodio a una concentración de aproximadamente 100 mM a aproximadamente 165 mM, un agente crioconservante que es un azúcar, opcionalmente trehalosa, y un poloxámero o polisorbato a una concentración de menos del 0,2% p/v. Reivindicación 13: Una composición farmacéutica que comprende partículas de AAV recombinante (rAAV) a una concentración de al menos 1E13 vg/ml a aproximadamente 1E14 vg/ml, un agente tampón, un agente de isotonicidad, un agente crioconservante y un tensioactivo que es estable durante el almacenamiento a aproximadamente -60ºC (menos sesenta grados centígrados) o menos durante al menos aproximadamente 1 año, 1,5 años o 2 años. Reivindicación 18: Una composición farmacéutica que comprende partículas de rAAV a una concentración de aproximadamente 6E13 vg/ml, fosfato de sodio 10 mM, cloruro de sodio 120 mM, trehalosa dihidrato 74 mM y poloxámero 188 al 0,1% p/v.
ARP210100824A 2020-04-03 2021-03-31 Tratamiento de la fenilcetonuria con aav y formulaciones terapéuticas AR122409A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063005049P 2020-04-03 2020-04-03

Publications (1)

Publication Number Publication Date
AR122409A1 true AR122409A1 (es) 2022-09-07

Family

ID=75674959

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210100824A AR122409A1 (es) 2020-04-03 2021-03-31 Tratamiento de la fenilcetonuria con aav y formulaciones terapéuticas

Country Status (3)

Country Link
AR (1) AR122409A1 (es)
TW (1) TW202144575A (es)
WO (1) WO2021202943A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6994018B2 (ja) 2016-07-26 2022-01-14 バイオマリン ファーマシューティカル インコーポレイテッド 新規アデノ随伴ウイルスキャプシドタンパク質
TW202016314A (zh) 2018-05-09 2020-05-01 美商拜奧馬林製藥公司 治療苯丙酮尿症之方法
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
IL301677A (en) 2020-10-01 2023-05-01 Genzyme Corp Human pah expression cassette for treatment of pku by liver-directed gene replacement therapy
AU2021372262A1 (en) 2020-11-02 2023-06-01 Biomarin Pharmaceutical Inc. Process for enriching adeno-associated virus
CN119072302A (zh) * 2022-03-14 2024-12-03 瑞泽恩制药公司 Aav药物产品的冻干制剂
CN116656740A (zh) * 2023-05-30 2023-08-29 浙江大学 一种腺相关病毒基因治疗载体及其在制备治疗苯丙酮尿症的药物中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US955734A (en) 1909-04-26 1910-04-19 Joseph Wolkerstorfer Display-rack.
IE58011B1 (en) 1983-05-27 1993-06-16 Texas A & M Univ Sys Method for producing a recombinant baculovirus expression vector
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
ZA848495B (en) 1984-01-31 1985-09-25 Idaho Res Found Production of polypeptides in insect cells
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
ATE497536T1 (de) 2001-10-16 2011-02-15 Nat Inst Of Advanced Ind Scien Neue n-acetylglucosamin transferase, codierende nukleinsäuren, spezifische antikörper, sowie verwendung zur krebsdiagnose
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
BRPI0214119B8 (pt) 2001-11-13 2021-05-25 Univ Pennsylvania vírus adenoassociado recombinante, método de geração do referido vírus e composição compreendendo o referido vírus
AU2003212708A1 (en) 2002-03-05 2003-09-16 Stichting Voor De Technische Wetenschappen Baculovirus expression system
AU2004290692A1 (en) 2003-11-17 2005-06-02 Biomarin Pharmaceutical Inc. Processes for preparing tetrahydrobiopterin, and analogs of tetrahydrobiopterin
MX2007005039A (es) 2004-11-17 2007-06-19 Biomarin Pharm Inc Formulacion de tableta estable.
US7531341B1 (en) 2006-06-12 2009-05-12 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7534595B2 (en) 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7560263B2 (en) 2007-08-17 2009-07-14 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
PE20091314A1 (es) 2008-01-07 2009-09-03 Biomarin Pharm Inc Metodo para sintetizar tetrahidrobiopterina
US7943379B2 (en) 2008-04-30 2011-05-17 Nationwide Children's Hospital, Inc. Production of rAAV in vero cells using particular adenovirus helpers
WO2013123503A1 (en) 2012-02-17 2013-08-22 The Children's Hospital Of Philadelphia Aav vector compositions and methods for gene transfer to cells, organs and tissues
JP6994018B2 (ja) 2016-07-26 2022-01-14 バイオマリン ファーマシューティカル インコーポレイテッド 新規アデノ随伴ウイルスキャプシドタンパク質
AU2017391165B2 (en) * 2016-11-04 2023-02-02 Takeda Pharmaceutical Company Limited Adeno-associated virus formulations
EP3562494A4 (en) 2016-12-30 2020-08-19 The Trustees Of The University Of Pennsylvania GENE THERAPY FOR THE TREATMENT OF PHENYLKETONURIS
TW202016314A (zh) 2018-05-09 2020-05-01 美商拜奧馬林製藥公司 治療苯丙酮尿症之方法
JP2021530548A (ja) * 2018-07-24 2021-11-11 ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics, Inc. 遺伝子治療製剤を生産するための系および方法
TW202103718A (zh) * 2019-04-19 2021-02-01 美商銳進科斯生物股份有限公司 腺相關病毒載體調配物及方法

Also Published As

Publication number Publication date
WO2021202943A1 (en) 2021-10-07
TW202144575A (zh) 2021-12-01

Similar Documents

Publication Publication Date Title
AR122409A1 (es) Tratamiento de la fenilcetonuria con aav y formulaciones terapéuticas
PE20241346A1 (es) Vectores del factor viii del virus adeno-asociado, particulas viricas asociadas y formulaciones que los comprenden
ES2263450T3 (es) Preparaciones de g-csf estabilizadas a largo plazo.
ES2345058T3 (es) Formulacion acuosa de hfsh.
JP7150804B2 (ja) プラミノーゲンを含む医薬組成物及びその使用
HRP20110801T1 (hr) Tekući oblik fsh
ECSP23041058A (es) Formulación subcutánea de anticuerpo anti-her2
JP2018138578A5 (es)
AR078161A1 (es) Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
MX2009012964A (es) Formulacion de peptido estable a alta temperatura.
RU2009101226A (ru) Составы антагониста vegf, подходящие для интравитреального введения
JP2013511522A (ja) ダプトマイシン製剤
BR0307898A (pt) Formulações de droga antibiótica oftálmica contendo um composto de ciclodextrina e cloreto de cetil piridìnio
US20180280479A1 (en) Stabilized external preparation comprising thymosin beta 4 as an active ingredient
BRPI0921429B1 (pt) Formulação farmacêutica liofilizada estável, e, método para preparar um fator liofilizado estável
AR040529A1 (es) Formulaciones de hgh en alta concentracion que contienen 1,2-propilenglicol
AR050959A1 (es) Estabilizacion de agentes inmunologicamente activos adyuvados con alumbre
HRP20230929T1 (hr) Stabilni pripravci semaglutida i njihova upotreba
PE20141265A1 (es) Formulaciones liofilizadas de fgf-18
ES2375706T3 (es) Composiciones de alfa 1-antitripsina y métodos de tratamiento que usan tales composiciones.
Prankerd et al. Pulmonary delivery of an ultra-fine oxytocin dry powder formulation: potential for treatment of postpartum haemorrhage in developing countries
CL2021001587A1 (es) Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf
AR127533A1 (es) INHIBIDORES DEL SARS-CoV-2 PARA EL TRATAMIENTO DE INFECCIONES POR CORONAVIRUS
JP2007511539A5 (es)
CL2024001520A1 (es) Nueva composición farmacéutica oral y régimen de dosificación para la terapia de enfermedades pulmonares intersticiales

Legal Events

Date Code Title Description
FB Suspension of granting procedure